212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin InvolvementChristopher J Edwards, C. Birbara, Francisco J. Blanco et al.|Lara D. Veeken|2014Cited by 29